GAITHERSBURG, MD--(Marketwired - April 13, 2015) - Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Vaxin develops vaccines for important public health and biodefense needs. Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin's CFO, she will grow the company's finance organization, oversee M&A activities, and drive interactions with the investor community.
"Elizabeth's appointment represents a significant milestone for Vaxin," said Bill Enright, Vaxin's president and CEO. "Our recent acquisition of Immune Targeting Systems (ITS), coupled with a $16 million funding infusion, has propelled the company into a new growth stage. It is critical now that we have an executive dedicated to supporting the growth with prudent financial management. Elizabeth's experience as a venture capitalist, coupled with her executive-level finance, business development, and operational expertise in our industry, makes her an ideal fit for this important role. We're delighted to welcome her to the team."
"This is an exciting time to join Vaxin as CFO," said Ms. Czerepak. "The company's two-vaccine platform strategy makes it uniquely positioned to address the emerging public health and biodefense challenges that the nation and the world will face in the coming years. I look forward to working closely with Bill and the excellent staff and investors at Vaxin as we collectively execute on our growth strategy."
A seasoned finance executive, Ms. Czerepak has led a broad range of initiatives at public and privately held companies. As a venture capital investor and board member at Bear Stearns Health Innoventures (BSHI), she played a key role in raising hundreds of millions of dollars in private financings and IPOs, and achieving $537 million and $364 million acquisitions of portfolio companies.
Before Vaxin, Ms. Czerepak served as CFO and chief business officer at Isarna Therapeutics BV and, earlier, as CFO and principal accounting officer at Cancer Genetics Inc. (CGI). Prior to CGI, she worked for nine years at JP Morgan Inc. and Bear Stearns, where she was managing director and general partner of BSHI, and an NASD registered representative. Earlier in her career, Ms. Czerepak was vice president of business development and a member of the U.S. executive board at BASF Pharma, and held senior-level finance, licensing, and corporate development positions at Hoffmann-La Roche and Merck & Co.
Ms. Czerepak has an MBA from Rutgers University and a BA magna cum laude from Marshall University.
Vaxin Inc. is a clinical stage biotechnology company developing next-generation vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary vaccine delivery platforms, Vaxin can rapidly design vaccines against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Vaxin's NasoVAXTM platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. Our DensigenTM T-cell vaccine platform technology is uniquely suited to direct the immune response against traditionally difficult vaccine targets, including chronic infections and cancer, by directing an individual's immune system against multiple target antigens instead of just one. Vaxin's vaccines are easily manufactured, highly stable, and provide a safe, effective alternative to current products. www.vaxin.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgement as of the date of this release. The company disclaims any intent or obligation to update these forward-looking statements.
President & CEO
Email: Email Contact